Joint modelling of longitudinal and competing risks data

Statistics in Medicine

Volumn 27, Issue 30, 2008, Pages 6426-6438

  Williamson, P R ^a   Kolamunnage Dona, R ^a   Philipson, P ^b   Marson, A G ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

Anti epileptic drugs; Competing risks; Drug titration; Joint modelling; Longitudinal data

Indexed keywords

CARBAMAZEPINE; LAMOTRIGINE; TRIAZINE DERIVATIVE;

ARTICLE; COMPUTER SIMULATION; EPILEPSY; HUMAN; LONGITUDINAL STUDY; METHODOLOGY; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; RISK FACTOR; STATISTICAL MODEL;

CARBAMAZEPINE; COMPUTER SIMULATION; EPILEPSY; HUMANS; LONGITUDINAL STUDIES; MODELS, STATISTICAL; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; RISK FACTORS; TRIAZINES;

EID: 63249095015     PISSN: 02776715     EISSN: 10970258     Source Type: Journal    
DOI: 10.1002/sim.3451     Document Type: Article

References (24)

1. Hogan JW, Laird NM. Model-based approaches to analysing incomplete longitudinal and failure time data. Statistics in Medicine 1997; 16:259-272.
2. Elashoff RM, Li G, Li N. An approach to joint analysis of longitudinal measurements and competing risks failure time data. Statistics in Medicine 2007; 26:2813-2835.
3. Diggle PJ, Sousa I, Chetwynd A. Joint modelling of repeated measurements and time-to-event outcomes: the fourth Armitage lecture. Statistics in Medicine 2007; DOI: 10.1002/sim.3131.
4. Tsiatis AA, Degruttola V, Wulfsohn MS. Modeling the relationship of survival to longitudinal data measured with error. Applications to survival and CD4 counts in patients with AIDS. Journal of the American Statistical Association 1995; 90:27-37.
5. Wulfsohn MS, Tsiatis AA. A joint model for survival and longitudinal data measured with error. Biometrics 1997; 53:330-339.
6. Wang Y, Taylor JMG. Jointly modelling longitudinal and event time data with application to acquired immunodeficiency syndrome. Journal of the American Statistical Association 2001; 96(455):895-905.
7. Slasor P, Laird N. Joint models for efficient estimation in proportional hazards regression model. Statistics in Medicine 2003; 22:2137-2148.
8. Henderson R, Diggle P, Dobson A. Joint modelling of longitudinal measurements and event time data. Biostatistics 2000; 1:465-480.
9. Xu J, Zeger SL. Joint analysis of longitudinal data comprising repeated measures and time to events. Applied Statistics 2001; 50(3):375-387.
10. Henderson R, Diggle P, Dobson A. Identification and efficacy of longitudinal markers for survival. Biostatistics 2002; 3(1):33-50.
11. Commission on antiepileptic drugs. Considerations on designing clinical trials to evaluate the place of new antiepileptic drugs in the treatment of newly diagnosed and chronic patients with epilepsy. Epilepsia 1998; 39:799-803.
12. Williamson PR, Smith CT, Josemir WS, Marson AG. Importance of competing risks in the analysis of anti-epileptic drug failure. Trials 2007; 8:12. DOI: 10.1186/1745-6215-8-12.
13. Marson AG, Al-Kharusi AM, Alwaidh M, Appleton R, Baker GA, Chadwick DW, Cramp C, Cockerell OC, Cooper PN, Doughty J, Eaton B, Gamble C, Goulding PJ, Howell SJL, Hughes A, Jackson M, Jacoby A, Kellett M, Lawson GR, Leach JP, Nicolaides P, Roberts R, Shackley P, Shen J, Smith DF, Smith PEM, Tudur Smith C, Vanoli A, Williamson PR on behalf of the SANAD Study group. Carbamazepine, gabapentin, lamotrigine, oxcarbazepine or topiramate for partial epilepsy: results from the SANAD trial. The Lancet 2007; 369:1000-1015. DOI: 10.1016/S0140-6736(07)60460-7.
14. Williamson PR, Kolamnunnage-Dona R, Tudur Smith C. The influence of competing risks setting on the choice of hypothesis test for treatment effect. Biostatistics 2006; 8:689-694. DOI: 10.1093/biostatistics/kxl040.
15. Cross H, Ferrie C, Lascelles K, Livingston J, Mewasingh L. Old versus new antiepileptic drugs: the SANAD study. The Lancet 2007; 370:314.
16. French JA. First-choice drug for newly diagnosed epilepsy. The Lancet 2007; 369:970-971.
17. Perucca E, Alexandre V, Tomson T. Old versus new antiepileptic drugs: the SANAD study. Lancet 2007; 370:313.
18. Panayiotopoulos CP. Old versus new antiepileptic drugs: the SANAD study. The Lancet 2007; 370:313-314.
19. O'Donoghue MF, Sander JWAS. Lamotrigine versus carbamazepine in epilepsy. The Lancet 1995; 345:1300.
20. Faught E. Epilepsy drugs: getting it right the first time. Lancet Neurology 2007; 6:476-478.
21. Naumova EN, Must A, Laird NM. Tutorial in biostatistics: evaluating the impact of 'critical periods' in longitudinal studies of growth using piecewise mixed effects models. International Journal of Epidemiology 2001; 30(6):1332-1341.
22. Elashoff RM, Li G, Li N. An approach to joint analysis of longitudinal measurements and competing risks failure time data. Statistics in Medicine 2007; 26:2813-2835.
23. Dobson A, Henderson R. Diagnostics for joint longitudinal and dropout time modelling. Biometrics 2003; 59:741-751.
24. Tseng Y-K, Hsieh F, Wang, J-L. Joint modelling of accelerated failure time and longitudinal data. Biometrika 2005; 92:587-603.